Tenaya Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 18, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 18, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.
| TENAYA THERAPEUTICS, INC. | ||
| Date: March 18, 2024 | By: | /s/ Faraz Ali, M.B.A. |
|---|---|---|
| Faraz Ali, M.B.A. | ||
| Chief Executive Officer | ||
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Faraz Ali and Leone Patterson as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and substitution, for him or her and in his or her name, place, and stead, in any and all capacities (including his or her capacity as a director and/or officer of Tenaya Therapeutics, Inc.) to sign any or all amendments to this Annual Report on Form 10-K, and to file the same, with all exhibits thereto, and all other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as they, he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agents or any of them, or their, his, or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.
| Name | Title | Date |
|---|---|---|
| /s/ Faraz Ali, M.B.A. | Chief Executive Officer and Director(Principal Executive Officer) | March 18, 2024 |
| Faraz Ali, M.B.A. | ||
| /s/ Leone D. Patterson, M.B.A. | Chief Financial and Business Officer(Principal Financial and Accounting Officer) | March 18, 2024 |
| Leone D. Patterson, M.B.A. | ||
| /s/ Amy L. Burroughs | Director | March 18, 2024 |
| Amy L. Burroughs, M.B.A. | ||
| /s/ Jin-Long Chen, Ph.D. | Director | March 18, 2024 |
| Jin-Long Chen, Ph.D. | ||
| /s/ David V. Goeddel, Ph.D. | Director | March 18, 2024 |
| David V. Goeddel, Ph.D. | ||
| /s/ June Lee, M.D. | Director | March 18, 2024 |
| June Lee, M.D. | ||
| /s/ Karah Parschauer | Director | March 18, 2024 |
| Karah Parschauer | ||
| /s/ Deepak Srivastava, M.D. | Director | March 18, 2024 |
| Deepak Srivastava, M.D. | ||
| /s/ Catherine Stehman-Breen, M.D. | Director | March 18, 2024 |
| Catherine Stehman-Breen, M.D. | ||
| /s/ Jeffrey T. Walsh, M.B.A. | Director | March 18, 2024 |
| Jeffrey T. Walsh, M.B.A. | ||
| /s/ R. Sanders (Sandy) Williams, M.D. | Director | March 18, 2024 |
| R. Sanders (Sandy) Williams, M.D. | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.